RNAC
Cartesian Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RNAC
Cartesian Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on Immune System
7495 New Horizon Way, Frederick, MD 21703
--
Cartesian Therapeutics, Inc., was incorporated in Delaware. The company is a clinical-stage company that has pioneered RNA cell therapies for the treatment of autoimmune diseases. The company's main asset, Descartes-08, is a potential first-in-class, RNA engineered chimeric antigen receptor T-cell therapy (rCAR-T), which is in Phase 2 clinical development in patients with generalized myasthenia gravis, and plans to conduct additional Phase 2 studies in systemic lupus erythematosus and ocular autoimmune and vascular autoimmune basket trials. Cartesian operates a wholly owned state-of-the-art cGMP manufacturing facility in Gaithersburg, Maryland.
Company Financials
EPS
RNAC has released its 2025 Q3 earnings. EPS was reported at -1.38, versus the expected -0.63, missing expectations. The chart below visualizes how RNAC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RNAC has released its 2025 Q3 earnings report, with revenue of 452.00K, reflecting a YoY change of 16.80%, and net profit of -35.90M, showing a YoY change of -48.46%. The Sankey diagram below clearly presents RNAC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
